Cibinetide Safe for Diabetic Macular Edema, Shows Promise in Subgroup Analysis

Diabetic Macular Edema (DME) is a leading cause of vision impairment and blindness in individuals with diabetes, characterized by fluid accumulation and swelling in the macula, the central part of the retina. This condition is driven by chronic inflammation and increased vascular permeability. Current treatments, often involving repeated intravitreal injections, can be invasive and burdensome for patients. There is a pressing need for novel, less invasive therapeutic strategies that can effectively target the underlying inflammatory processes and reduce vascular leakage in DME.